The association between circulating MicroRNA‐150 level and cholangiocarcinoma

• Published in: Journal of clinical laboratory analysis Vol. 34; no. 11; pp. e23397 - n/a
• Main Authors: Salem, Perihan El Sayed, Ghazala, Rasha Abdelmawla, El Gendi, Ahmed Mohamed, Emara, Doaa Mokhtar, Ahmed, Nesma Mahmoud
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2020; John Wiley and Sons Inc
• Subjects: Abdomen; Age; Antigens; Biomarkers; Cell cycle; Cholangiocarcinoma; Cholangitis; Colorectal cancer; Diagnosis; diagnosis of CCA; Laboratories; MicroRNAs; miRNA; Patients; Phenols; risk factors for CCA; serum CA19‐9; serum MiRNA‐150; Tomography; Tumor markers; Tumorigenesis; Tumors; serum CA19-9; risk factors for CCA; diagnosis of CCA; serum MiRNA-150; cholangiocarcinoma
• ISSN: 0887-8013; 1098-2825; 1098-2825
• DOI: 10.1002/jcla.23397

Cholangiocarcinoma (CCA) is a rare tumor which requires a multimodality approach for its diagnosis. Carbohydrate antigen 19‐9 (CA19‐9) is currently the most commonly used tumor marker for CCA; nevertheless, it has certain limitations which need to be considered when using it as a tumor marker. MiRNA‐150 altered expression has been linked to the development and tumorigenesis of several cancers including CCA. This work aimed to study the serum level of CA19‐9 and miRNA‐150 expression in CCA patients and, also, to correlate their levels with tumor staging and different studied clinical and laboratory parameters. This work included 35 patients with CCA who were admitted to Hepatobiliary Unit, Alexandria Main University Hospital (Group I). Also, 35 age‐ and sex‐matched healthy subjects were included as a control group (Group II). All included subjects were submitted to measurement of serum CA19‐9 and MiRNA‐150 expression levels. Serum CA19‐9 levels showed an evident high median among CCA patients, while serum miRNA‐150 expression levels were evidently low among those patients. Moreover, combining miRNA‐150 with CA19‐9 made the accuracy of diagnosis of CCA much more reliable. Thus, miRNA‐150 can be considered as a non‐invasive, sensitive serum biomarker for the diagnosis of CCA especially when combined with CA 19‐9.